Obstructive sleep apnea is major problem causing snoring and hence sleep disturbances. It is a risk factor for heart diseases ,is significantly higher (4- to 10-fold) with obesity, especially with central obesity. The prevalence of obstructive sleep apnea in the population with type 2 diabetes may be as high as 23%, and the prevalence of any sleep-di-sordered breathing may be as high as 58% .Obstructive sleep apnea should be evaluated in indi-viduals with suggestive symptoms (e.g., excessive daytime sleepiness, snoring, and witnessed apnea). Sleep apnea treatment (lifestyle modification, continu-ous positive airway pressure, oral applian-ces, and surgery) significantly improves quality of life and blood pressure management. Recently, treatment with the dual GIP and GLP-1 RA tirzepatide has shown to substantially reduced sleep apnea severity .
